Peer-Reviewed Publication
Nat Rev Drug Discov2026September 21, 2026Journal Article
The evolving landscape of drug targets.
Liliana Halip1, Sorin Avram2, John P Overington3, Bissan Al-Lazikani4, Ramona Curpan1, Suman Sirimulla5, Alexei Pushechnikov5, Andrea Rosario Beccari6, Nikolay Savchuck5, Tudor I Oprea7,8,9
1Department of Computational Chemistry, Romanian Academy, 'Coriolan Drăgulescu' Institute of Chemistry Timișoara, Timișoara, Romania.
2Department of Computational Chemistry, Romanian Academy, 'Coriolan Drăgulescu' Institute of Chemistry Timișoara, Timișoara, Romania. sorin_avram@acad-icht.tm.edu.ro.
3Xyme AI Ltd, Oxford, UK.
4Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
5Expert Systems Inc., San Diego, CA, USA.
6Exscalate, Dompé farmaceutici, Milan, Italy.
7Expert Systems Inc., San Diego, CA, USA. tudor.oprea@dompe.com.
8Exscalate, Dompé farmaceutici, Milan, Italy. tudor.oprea@dompe.com.
9Department of Internal Medicine, University of New Mexico School of Medicine, Albuquerque, NM, USA. tudor.oprea@dompe.com.
Abstract
Since the turn of the century, drug discovery has been transformed by advances in genetics, genomics and proteomics, as well as automation, data science and the diversification of therapeutic modalities beyond synthetic small molecules and natural product derivatives. This transformation has led to the expansion of the drug target landscape, enabling advances in the treatment of many diseases, inc…
Create a free account to keep reading
Free members get 10 full research views every month across publications, clinical trials, FDA clearances, adverse events, and NIH grants. No credit card required.
Want unlimited research access? See Pro plans